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ScienceDirectChemical genetics is the use of biologically active small
molecules (chemical probes) to investigate the functions of
gene products, through the modulation of protein activity.
Recent years have seen significant progress in the application
of chemical genetics to study epigenetics, following the
development of new chemical probes, a growing appreciation
of the role of epigenetics in disease and a recognition of the
need and utility of high-quality, cell-active chemical probes. In
this review, we single out the bromodomain reader domains as
a prime example of both the success, and challenges facing
chemical genetics. The difficulty in generating single-target
selectivity has long been a thorn in the side of chemical
genetics, however, recent developments in advanced forms of
chemical genetics promise to bypass this, and other,
limitations. The ‘bump-and-hole’ approach has now been used
to probe — for the first time — the BET bromodomain subfamily
with single-target selectivity and may be applicable to other
epigenetic domains. Meanwhile, PROTAC compounds have
been shown to be significantly more efficacious than standard
domain inhibitors, and have the potential to enhance target
selectivity.
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Chemical genetics in epigenetics
Through the use of chemical probes, chemical genetics
allows elucidation of the biological role and therapeutic
significance of proteins [1,2]. Chemical genetics is similar
to classical genetics (knock-outs, mutations, knock-downs)Current Opinion in Chemical Biology 2016, 33:186–194 [3], but alters a different point in the gene–protein–pheno-
type relationship. Classical genetics typically intervenes
upon the gene itself (or RNA), altering or down-regulating
the protein as a result; whereas chemical genetics affects the
behavior of the protein directly.
Chemical genetics has several advantages over classical
genetics [3]; such as reversibility, tuneability and greater
spatial and temporal control. Genetic tools have addition-
al drawbacks, such as the potential lethality of knock-
outs. However, chemical probes are typically less selec-
tive than targeted gene-modification and may be active
against several related proteins, preventing the connec-
tion of specific functions and phenotypes with specific
proteins. Consequently, one of the greatest, and still
unmet, challenges facing chemical genetics is the diffi-
culty of generating small-molecules with exquisite single-
target selectivity [2,4].
Our growing understanding of the links between epige-
netics and disease has driven the demand for well-char-
acterised chemical tools targeting epigenetic proteins [5,6].
Many epigenetic proteins — writers, readers and erasers of
epigenetic marks [5–7] — have emerged as potential drug
targets, and require chemical target validation. However,
the application of chemical genetics to study epigenetic
proteins faces several challenges (Figure 1a). Firstly, the
difficulty in generating single-target selectivity is magnified
in epigenetic systems, where many domains are clustered in
large families with highly conserved substrate-binding sites
[6]. This situation is similar to that of protein kinases and
readers of protein phosphorylation (SH2 domains) where
related proteins possess near-identical ligand-binding
sites despite different functions and substrates [8,9].
Second, probing an epigenetic target may result in com-
plex phenotypic changes. The target may act on a large
number of epigenetic marks at multiple loci throughout
the genome, making it difficult to identify the gene(s)
causing the phenotype of interest [10] (Figure 1a). Last-
ly, epigenetic regulation is highly context specific [11]
and the biological effects of a chemical probe will greatly
depend on the cell type and state. For a chemical genetic
approach to be successful it is vital that appropriate
cellular or in vivo models are selected to address the
system of interest.
This review will illustrate recent progress and highlight
novel approaches being developed to address the chal-
lenges facing chemical genetics for epigenetics.www.sciencedirect.com
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Chemical genetics, and its use in epigenetics. (a) Epigenetic protein regulates expression of multiple genes by reading, writing or erasing epigenetic
marks at various gene loci. Chemical probe inhibits epigenetic protein function, altering epigenetic state of loci and the expression of relevant genes.
Hence, a chemical probe facilitates the linking of the target protein to the phenotype of interest. However, linking the target and the resulting
phenotype is complicated both by the target regulating multiple loci/genes and off-target inhibition of related proteins. (b) In forward chemical genetics
(left panel) a library of diverse small-molecules is screened against cells. A probe is found to elicit the desired phenotype. The target protein of the
probe is then identified, potentially through a chemical pulldown with a probe conjugated to beads. In reverse chemical genetics (right panel) a probe
is designed and optimized for a protein of interest. This probe is then used in a variety of cells to see what phenotype it induces. Inset panel displays
two examples of chemical probes targeting epigenetic proteins. JQ1 inhibits the BET bromodomains and was developed from the product of a
phenotypic screen. UNC1215 targets the methyl-lysine reader L3MBTL3 and was developed through a target-driven approach.Forward and reverse chemical genetics in
epigenetics
Both chemical and classical genetics can be described
as acting in a ‘forward’ or ‘reverse’ fashion [1,3]www.sciencedirect.com (Figure 1b). The forward approach involves phenotypic
screens in which random mutations or diverse small-
molecule libraries are employed to achieve a desired
phenotype. The mutated gene, or affected protein,Current Opinion in Chemical Biology 2016, 33:186–194
188 Chemical Genetics and Epigeneticsresponsible for said phenotype is then identified. By
contrast, the reverse approach begins with a known
target gene or protein, the function of which is then
specifically perturbed through chemical or genetic
methods.
The power of forward chemical genetic approaches to
study epigenetics is illustrated by many examples that
have resulted in the identification of small-molecules
targeting epigenetic proteins. Here we focus on epige-
netic reader domains, in particular bromodomains (which
recognize acetyl-lysine), but the same principles have
applied to other epigenetic proteins, such as writers
and erasers, including HDACs [12,13]. Seeking a
small-molecule means to suppress inflammation, a team
at GSK initiated a phenotypic screen looking for up-
regulators of ApoA1 [14], using a HepG2 cell line and
a luciferase reporter gene. This screen identified benzo-
diazepine (BZD) compounds as hits, which were used in a
‘chemical pulldown’ approach to identify the bromodo-
mains of BET (bromodomain and extra-terminal motif)
proteins BRD2, BRD3 and BRD4 as targets. This led to
the development of I-BET762 as a BET inhibitor [15]. In
parallel, Mitsubishi Tanabe reported thienotriazolodia-
zepine compounds as BET bromodomain inhibitors that
cause growth arrest in acute myeloid leukemia and NUT
Midline Carcinoma cell lines [16]. Further work by
Bradner, the SGC and collaborators pursuing a potential
NUT-midline carcinoma treatment, led to the report of
JQ1 (Figure 1b) as a pan-selective BET inhibitor [17].
These discoveries demonstrated the potential of pheno-
typic screens to identify important roles of epigenetic
mediators. They also highlighted the druggability of BET
proteins and started a new wave of interest in the science
community using these chemical tools to probe for BET
functions.
The important biological roles of epigenetic proteins,
coupled with the success of phenotypic screens at link-
ing these targets to disease, have motivated growing
efforts to identify their endogenous substrates and de-
orphanize them of small-molecule probes. Following the
discovery of JQ1 [17] and I-BET762 [15], several inhi-
bitors targeting BET and other bromodomains have
been developed, guided by an abundance of high-reso-
lution crystal structures. Said inhibitor design has re-
cently been comprehensively reviewed [18–20]. Reverse
chemical genetics has also been employed to target
readers of methyl-lysine marks such as chromodomains,
PHD fingers and MBT domains [21–24]. While most
of these probes have not yet been used to address
biological questions, in some cases they have revealed
interesting biochemical insights. For example,
UNC1215 (Figure 1b, a selective probe for the meth-
yl-lysine reader L3MBTL3) has suggested a possible
polyvalent method of substrate recognition [25] and
revealed that L3MBTL3 functions as a dimer [26].Current Opinion in Chemical Biology 2016, 33:186–194 Chemical probes as chemical tools
Chemical probes have been used to investigate the func-
tion and importance of the BET proteins in a wide range
of contexts, from cancer and inflammation to neurology
and reproductive biology. These studies have highlighted
the role that BET proteins play in processes, such as cell
growth and differentiation [27], through the modulation
of many signaling pathways such as C-MYC, NF-kB and
the Jak/STAT pathway. The wide range of cell-types and
tissues these compounds have proven useful in is itself
evidence for the benefits of making chemical probes
available to as wide a range of researchers as possible.
These compounds are pan-selective BET inhibitors,
which prevents specific phenotypes being linked to a
specific BET protein or bromodomain. This has been
compensated for somewhat by the use of complimentary
genetic tools (KO, RNAi) to identify the relevant protein
[28–30]; and by a mutant-sensitive chemical genetic
approach [31], discussed later. Some selectivity within
the BET subfamily has been reported [32–35] but said
probes still lack single-target specificity.
Chemical probes can be used for many applications
beyond mere target inhibition (Figure 2). Compounds
bearing an affinity tag can be used for chemical pulldowns
of the target protein [14,36]. These pull-downs can also
identify splice-variants of the target protein, the subunits
it may associate with and potentially related proteins with
sufficiently similar binding sites. These ‘pulled down’
proteins can then also be analyzed for the presence of
post-translational modifications. A chemical pulldown
using the probe UNC1215 revealed an interaction be-
tween L3MBTL3 and BCLAF1 [25], while UNC0965 (a
biotinylated G9a probe) gave a higher pulldown signal/
noise ratio than a G9a antibody [37]. Recently, a UV-
triggered JQ1 cross-linker was developed [38], and used
to identify potential off-targets of JQ1.
Anders et al. [36] designed a biotinylated JQ1 probe for
use in a ChIPseq experiment, and were able to show the
localization of JQ1 and its targets throughout the chro-
mosome. The JQ1 cross-linker mentioned previously [38]
has also been used to conjugate BET proteins to a
fluorophore, for use in live-cell fluorescence microscopy.
Fluorescent probes provide an alternative to the estab-
lished practice of using GFP-fusion constructs in micros-
copy and may prove advantageous, such as when the
target protein is not genetically pliable or the GFP tag
impacts the wild-type protein function.
Advanced chemical genetics
The use of chemical probes, both in forward and reverse
chemical genetics, has revealed much about the function of
epigenetic proteins, but has traditionally been restricted to
a conventional target:inhibitor modality. More advanced
forms of chemical genetics are being developed that offer
new opportunities to bypass inherent limitations of targetwww.sciencedirect.com
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Chemical probes as chemical tools. (a) Chemical probes used in vivo
to investigate protein function. Inactive analogs can be used to control
for off-target effects. (b) Chemical probe conjugated to bead, for use
in protein pulldown (shown via western blot). (c) Fluorescent probe
used for fluorescence microscopy, showing cellular localization of
target. (d) Probe with affinity tag (e.g. biotin-streptavidin) used in
ChIPseq experiment, showing probe localization along genome. (e)
Modified probe used in competitive binding assay (e.g. fluorescence
polarization), for library screening.inhibition and provide an additional level of biological
insights.
Bump-and-hole approach
To overcome the challenge of achieving selectivity
against homologous, highly similar binding sites, an or-
thogonal protein:ligand pair can be generated. In the so-
called bump-and-hole approach [39], which has foundwww.sciencedirect.com attention early on with cofactor-dependent enzymes
[40,41], a small hole within the binding site is generated
by site-directed mutagenesis. An allele-specific probe can
then be obtained by introducing a compensatory bulky
modification to the ligand. This chemical group will be
expected to produce steric clashes and abolish binding to
the wild-type protein, but be accommodated by the
mutant (Figure 3).
The bump-and-hole technique has been applied to epi-
genetic enzymes and their cofactor ligands as a mean to
identify their specific substrate proteins. For example, the
methyl-donor SAM (S-adenosyl-L-methionine), can be
modified at various positions by introducing a sterically
demanding group which must then be accommodated by
a PMT (protein methyl transferase) enzyme. Modifica-
tion on the adenosyl-N6 position allowed study of the
methylation of substrates by yeast RMT1 [41], and by
modifying the 20-hydroxyl and 30-hydroxyl groups of the
ribose unit of SAM the enzymatic activity of the histone
methylase vSET was studied [42]. In another approach
PMTs were engineered to process methyl sulfonium
SAM-analogs allowing the enzyme to transfer distinct
chemical groups (e.g. alkyne units) to the substrate that
could then be used to pulldown target proteins [43–45].
This helped to identify the genome-wide chromatin-
modifying activities of G9a and GLP1, through next
generation sequencing of the enriched pulldown samples
of chromatin DNA [45]. A similar approach was applied to
KATs (lysine acetyltransferases) where synthetic Acetyl-
CoA surrogates where used to label KAT cellular targets
[46].
This technique can also be used to create chemical probes
with single-target selectivity. Baud et al. [31] succeeded
in creating a derivative of the BET inhibitor I-BET762/
JQ1 selective for BET bromodomains possessing a dis-
tinct leucine/alanine mutation. Importantly, this selectiv-
ity was controllable and achieved over the entire BET
subfamily. Using this approach it was shown that small-
molecule targeting of the N-terminal bromodomain alone
is sufficient to displace BRD4 from chromatin [31]. This
marks both the first time that single BET proteins and
their individual bromodomains can be targeted selec-
tively by a small-molecule and also the first example of
the bump-and-hole approach being applied to a protein–
protein interaction. This approach may be applicable to
other bromodomains or epigenetic reader domains, allow-
ing links between specific proteins and phenotypes to be
shown with greater confidence than before.
Application of the bump-and-hole approach faces several
challenges. Both the nature of the mutation and the
nature of the bump must be balanced to find a compro-
mise between two extremes. More sizable mutations to
generate larger ‘holes’ will probably make selective li-
gands easier to generate. However these mutations mayCurrent Opinion in Chemical Biology 2016, 33:186–194
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Selective target inhibition via bump-and-hole. (a) Pan-selective probe binds multiple related proteins. This generates a (potentially complex)
phenotypic change. (b) Chemical probe is modified to incorporate a ‘bump’, and target protein is mutated to introduce a ‘hole’. (c) Bumped probe
binds only the mutated target, allowing the resulting phenotypic change to be connected to a single protein. Inset panel illustrates two successful
examples of bumped molecules developed against mutated epigenetic domains.disrupt the structure and function of the target protein,
complicating the interpretation of results and potentially
rendering mutant cell lines non-viable. The ‘bump’
meanwhile must be balanced between potency, selectiv-
ity and physiochemical properties. Larger and more ste-
rically demanding modifications will potentially have a
greater impact on reducing wild-type inhibition but could
also reduce the potency against the mutant proteins.Current Opinion in Chemical Biology 2016, 33:186–194 Bulkier bumps will also make the compound more lipo-
philic, a trait associated with pharmacokinetic liabilities.
It is not currently understood how broadly applicable the
bump-and-hole system may be. Results with BET bro-
modomains show that not all binding site residues can be
mutated to achieve acceptable outcomes [34], with a
conserved leucine residue from the ZA loop [31]
being the first one to both allow single-target selectivitywww.sciencedirect.com
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function.
PROTAC approach
Small molecules can be designed to induce intracellular
protein degradation, leading to the destruction of a targetFigure 4
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Chemically induced protein degradation via PROTAC. A chemical probe tar
ligase are connected by a linker, forming a PROTAC molecule. This PROTA
complex in which the target is ubiqutinylated. The polyubiquitinylated target
successful examples of PROTAC molecules targeting BET proteins for degr
(ARV-825 and dBET1).
www.sciencedirect.com protein. These so-called PROTACs (proteolysis targeting
chimeras) [47] are heterobifunctional compounds consist-
ing of a moiety binding an E3 ubiquitin ligase linked to
another that binds the target of interest, thus marking the
target for degradation by the proteasome (Figure 4).
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geting the protein-of-interest and a probe targeting an E3 Ubiquitin
C then binds both the target and ligase proteins, forming a ternary
 is then degraded by the proteasome. The inset panel illustrates
adation by recruiting E3 ligases such as VHL (MZ1) and cereblon
Current Opinion in Chemical Biology 2016, 33:186–194
192 Chemical Genetics and Epigeneticsdegradation have employed introduction of hydrophobic
degrons such as adamantyl moieties or Boc-protected
arginines [47].
Unlike conventional inhibitors, PROTAC molecules act
substoichiometrically via a catalytic mechanism [48]. As a
result, the concentration required for PROTACs to be
active in cells tend to be lower compared to those needed
to be reached and maintained with inhibitors, leading to
fewer off-target effects and a more selective chemical
intervention on the desired target. Another attractive fea-
ture of this advanced form of chemical genetics is that it
achieves a chemical knock-down directly at the posttrans-
lational level. This intervention is expected to phenocopy
more closely the effect of conventional genetic knock-out
and knock-down strategies, but without interfering direct-
ly on the DNA or RNA. Finally, PROTACs can function
regardless of where on the target protein they bind. Unlike
conventional inhibitors they do not need to bind to a
functional site on the target protein, which may aid in
the targeting of poorly druggable protein–protein interac-
tions that are common in epigenetic systems.
The PROTAC approach has recently been applied suc-
cessfully to the field of epigenetics, with three comple-
mentary studies demonstrating effective targeting of BET
proteins [49,50,51]. Using JQ1 and high-affinity li-
gands that had been designed against the VHL (von
Hippel-Lindau) E3 ligase, our laboratory developed a
series of PROTACs that exhibited rapid, reversible and
long-lasting destruction of BET proteins [49]. Interest-
ingly these compounds could induce potent and preferen-
tial removal of Brd4 over a suitable concentration window,
leaving the homologous Brd2 and Brd3 relatively un-
touched and leading to more Brd4-specific response in
cancer cells [49]. The most potent compound, MZ1, was
active at a sufficiently low concentration not to induce
stabilization and transcriptional activation of HIF-1a, the
natural substrate of VHL. In parallel studies, Winter et al.
[50] and Lu et al. [51] tethered the same BET inhibitor
scaffold to a ligand for a different E3 ligase, cereblon,
yielding highly potent pan-BET degraders dBET1 and
ARV-825, respectively. BET-degrading PROTACs exhib-
ited superior antiproliferative efficacy in cellular and
mouse models of c-MYC driven lymphomas and leukemias
compared to their parent BET inhibitors [50,51].
Together, these important studies demonstrate that in-
duced target degradation can elicit a more pronounced
and potentially more target-specific biological response
than domain-targeted chemical inhibition. In particular,
the reported VHL-based BET PROTACs provide first
proof-of-concept for turning non-selective or pan-selec-
tive inhibitors into more selective degraders.
The design and practical implementation of PROTACs
pose unique challenges. Because of their higher molecularCurrent Opinion in Chemical Biology 2016, 33:186–194 weight PROTACs would be expected to display poorer
DMPK properties than their smaller constituent ligands
(for example faster metabolic clearance). These potential
liabilities could impair efficacy in vivo and limit their
therapeutic development. Assuming that PROTAC linker
domains are not involved in ligase or target binding,
different forms of chemical linkers could be used to fi-
ne-tune pharmacokinetic properties in addition to target
degradation efficacy. Another difficulty in PROTAC de-
sign is the lack of a practical, rapid and robust assay for
measuring target-degradation activity beyond low-
throughput western blotting or expensive chemoproteo-
mics by mass spectrometry. Furthermore, in vitro ubiqui-
tylation assays are typically low-throughput and non-
quantitative. On the other hand, the affinity of PROTAC
compounds for purified target or ligase proteins can be
readily obtained using conventional biophysical/biochem-
ical techniques, and ternary-complex formation can poten-
tially be quantified through AlphaScreen [50] or FRET
techniques [52]. Finally, PROTACs suffer from the so-
called ‘hook-effect’ [49,51] wherein at high concentra-
tions formation of binary complexes (PROTAC:target and
PROTAC:ligase) competes with and eventually surpass
the formation of the productive ternary complex.
Conclusion and future perspectives
Chemical genetics can help to elucidate and understand
the function of epigenetic proteins and their role and
significance in disease, but epigenetic targets pose distinct
challenges. Many attractive epigenetic proteins remain to
be successfully probed by a small molecule, suggesting
their inherently low druggability. Conversely, within those
families that have proven druggable, such as HDACs and
bromodomains, issues of target selectivity remain to be
addressed. In future it will be important to improve upon
and extend beyond the established small-molecule target-
ing paradigm, that is, single domain-focused chemical
inhibition. More advanced and sophisticated ways of car-
rying out chemical genetics, such as the bump-and-hole
and PROTAC approaches, have shown to allow for more
selective targeting and improve on chemical probe efficacy.
We anticipate that combining these advances in chemical
genetics with the recent developments in genetic tools
such as CRISPR-Cas9 gene editing and refined ChIP-Seq
methods for genome-wide mapping will truly enable scien-
tists to push the frontiers of the field, ultimately increasing
the level and confidence of epigenetic target validation.
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